In this review:
Neoadjuvant erlotinib for stage IIIA-N2 EGFR-mutant NSCLC
Neoadjuvant nivolumab ± ipilimumab for resectable NSCLC
PACIFIC study: does post-RT to durvalumab randomisation time alter efficacy?
ALESIA: alectinib vs crizotinib in treatment-naïve ALK+ advanced NSCLC
Lorlatinib in ROS-1-positive advanced NSCLC & ROS-1 kinase mutations
FLAURA: mechanisms of acquired resistance to first-line osimertinib
AURA3: osimertinib resistance mechanisms in EGFR T790M advanced NSCLC
KEYNOTE-010: long-term outcomes for pembrolizumab in advanced NSCLC
Pembrolizumab in performance status 2 patients with NSCLC
Carboplatin + nab-paclitaxel ± atezolizumab first-line in advanced non-squamous NSCLC
B-F1RST: is bTMB a predictive biomarker for atezolizumab in 1L NSCLC?
Please login below to download this issue (PDF)